ClinicalTrials.gg
TerminatedNCT00954915Updated Feb 10, 2022Results posted

Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis

A Phase 1/2 interventional study of teplizumab in Psoriasis, sponsored by MacroGenics. Terminated at 2 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-02-10.

Sponsored by MacroGenics · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Injection site reaction met protocol-defined stopping criteria.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.

Enrollment
661st of 673
1 · median 77
Started
2009
with 29 others
Phase 1/2
13 of 764
none open now
Registered
144th of 764
by date

Among the 764 studies in Psoriasis with a site in United States, this one is the 661st largest by enrollment of the 673 interventional ones that give a count, is one of 30 that started in 2009, is one of 13 in phase 1/2, and was the 144th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 764 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether teplizumab is safe when administered subcutaneously (by needle under the skin) in subjects with psoriasis. The study will also evaluate how long teplizumab stays in the blood and how long it takes for it to leave the body, what is the highest dose that can safely be given, and whether it improves psoriasis.

Read the detailed description

This study will test the hypotheses that therapeutic modulation of T-cell function by teplizumab is well tolerated in subjects with moderate or more severe psoriasis, and that this treatment ameliorates the immunopathology of psoriasis. This study will evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous (SC) administration for 6 days. Once the SC maximum tolerated dose is identified, this dose will be administered to a cohort of subject by intravenous for comparison of PK and PD.

03

Conditions studied

  • Psoriasis

Keywords

  • chronic plaque psoriasis
  • psoriatic arthritis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic plaque psoriasis that has been present for more than 6 months and involves at least 10% Body Surface Area (BSA).
  • Baseline LS-PGA score of moderate or greater severity.
  • Weight \<= 125 kg (276 lb) and a BSA \<= 2.5 m\^2.

Exclusion criteria

Exclusion Criteria:

  • flare of psoriasis during the 12 weeks before enrollment.
  • Guttate, erythrodermic, palmoplantar, or pustular (von Zumbusch) psoriasis
  • Orally administered systemic psoriasis therapy or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks before enrollment.
  • Prior administration of a biologic agent/monoclonal antibody within 12 weeks before enrollment or 5 half-lives of the agent, whichever is greater.
  • Prior otelixizumab, OKT®3, or teplizumab.
  • Treatment within the last 30 days with a non-biologic drug or device that has not received regulatory approval for any indication at the time of study entry or are unwilling to forgo experimental treatment other than teplizumab during this study.
  • Treatment with within 8 weeks before enrollment or during study; vaccination with an antigen or killed organism during the study, within 8 weeks before enrollment, or 8 weeks after dosing.
  • Evidence of active infection.
  • Positive IgM test for hepatitis A.
  • History of or positive test for , C, or D.
  • History of or positive test for .
  • Are , have had recent or current serious systemic or local infection, clinical or radiological evidence of active tuberculosis, or evidence of latent TB infection.
  • History of chronic liver disease, peripheral vascular disease, cerebrovascular disease, cardiovascular disease, or epilepsy.
  • Current serious or unstable illnesses or allergies.
  • Clinically significant laboratory abnormalities.
  • Presence of serological reactivity to teplizumab (in subjects previously treated with therapeutic antibodies).
  • Clinically significant abnormalities.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    teplizumab

    Anti CD-3 monoclonal antibody

    Biological: teplizumab

Interventions

  • Biologicalteplizumab

    Cohorts 1-5: escalating doses of subcutaneously administered teplizumab; cohort 6: intravenous administration of maximum tolerated subcutaneous dose.

    Also known as: MGA031

06

What researchers measure

Primary outcomes

  1. Adverse Events (AE)

    Primary endpoints include safety data such as vital signs, physical examinations, electrocardiograms, AE reports, and laboratory test results.

    Time frame: Day 0 through Day 84

Secondary outcomes

  1. Number of Participants Improved on Lattice System Physician's Global Assessment (LS-PGA)

    The LS-PGA score is determined by estimating the extent of body surface area involved by psoriasis and rating plaque qualities (elevation, erythema, scaling) averaged over the entire body. LS-PGA score is then determined using available software. LS-PGA ranks involvement on an 8 point scale from clear, almost clear, mild, mild to moderate, moderate, moderate to severe, severe, and very severe. Participants who have an improvement of one or more steps in the LS-PGA will be considered to have met the primary criteria for a clinical response.

    Time frame: Day 0, 14, 28, 63 and 84

  2. Number of Participants Improved on the Psoriasis Area and Severity Index (PASI)

    The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of plaque scale, erythema, and plaque induration (thickness) in each region, yielding an overall score of 0 for no psoriasis to a maximum of 72 for severe disease.

    Time frame: Day 0, 14, 28, 63 and 84

  3. Physician's Global Assessment (PGA)

    The PGA rates the subject's psoriasis relative to baseline as 1 (100% clearing), 2 (excellent: 75% through 99% clearing with striking improvement), 3 (good: 50% through 74% clearing with moderate improvement), 4 (fair: 25% through 49% clearing with slight improvement), 5 (poor: 0% through 24% clearing with little or no change), or 6 (worsening). Involvement of body-surface area, induration, scaling, and erythema are taken into account.

    Time frame: Day 0, 14, 28, 63 and 84

  4. Teplizumab Blood Levels

    Time frame: Day 0 through Day 84

07

Results

Posted Apr 19, 2012
Limitations and caveats
This study was terminated, with only 1 subject enrolled, due to meeting the study criteria for discontinuation regarding local or regional injection site reactions.

Participant flow

Recruitment began at two academic institutions in April 2010 and was halted on December 17, 2010 after the first subject had an injection site reaction that met study stopping criteria.

Participant flow — Overall Study
MilestoneTeplizumab
Started1
Completed1
Not completed0

Outcome measures

PrimaryAdverse Events (AE)

Primary endpoints include safety data such as vital signs, physical examinations, electrocardiograms, AE reports, and laboratory test results.

Time frame:
Day 0 through Day 84
Reported as:
Number · Participants
Adverse Events (AE)
ParticipantsTeplizumab
Adverse Events (AE)1
SecondaryNumber of Participants Improved on Lattice System Physician's Global Assessment (LS-PGA)

The LS-PGA score is determined by estimating the extent of body surface area involved by psoriasis and rating plaque qualities (elevation, erythema, scaling) averaged over the entire body. LS-PGA score is then determined using available software. LS-PGA ranks involvement on an 8 point scale from clear, almost clear, mild, mild to moderate, moderate, moderate to severe, severe, and very severe. Participants who have an improvement of one or more steps in the LS-PGA will be considered to have met the primary criteria for a clinical response.

Time frame:
Day 0, 14, 28, 63 and 84

No measurements were reported for this outcome.

SecondaryNumber of Participants Improved on the Psoriasis Area and Severity Index (PASI)

The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of plaque scale, erythema, and plaque induration (thickness) in each region, yielding an overall score of 0 for no psoriasis to a maximum of 72 for severe disease.

Time frame:
Day 0, 14, 28, 63 and 84

No measurements were reported for this outcome.

SecondaryPhysician's Global Assessment (PGA)

The PGA rates the subject's psoriasis relative to baseline as 1 (100% clearing), 2 (excellent: 75% through 99% clearing with striking improvement), 3 (good: 50% through 74% clearing with moderate improvement), 4 (fair: 25% through 49% clearing with slight improvement), 5 (poor: 0% through 24% clearing with little or no change), or 6 (worsening). Involvement of body-surface area, induration, scaling, and erythema are taken into account.

Time frame:
Day 0, 14, 28, 63 and 84

No measurements were reported for this outcome.

SecondaryTeplizumab Blood Levels
Time frame:
Day 0 through Day 84

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Teplizumab—0/1 (0%)1/1 (100%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventTeplizumab
Injection site reactionSkin and subcutaneous tissue disorders1/1
C-reactive protein increasedInvestigations1/1
Injection site reaction condition aggravatedSkin and subcutaneous tissue disorders1/1
PyrexiaGeneral disorders1/1
NauseaGastrointestinal disorders1/1
VomitingGastrointestinal disorders1/1
HeadacheNervous system disorders1/1
HypotensionBlood and lymphatic system disorders1/1
Neutrophil count increasedInvestigations1/1
Lymphocyte count decreasedInvestigations1/1

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Teplizumab
<=18 years0
Between 18 and 65 years1
>=65 years0
Age, Continuous
Age, Continuous(years)Teplizumab
Mean43 ± 0
Sex: Female, Male
Sex: Female, Male(Participants)Teplizumab
Female1
Male0
08

Study locations

2 sites
  • University of Michigan Medical Center
    Ann Arbor, Michigan 48109, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2009
First posted
Aug 7, 2009
Start
Dec 2009
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Results first posted
Apr 19, 2012
Last update
Feb 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00954915
Lead sponsor
MacroGenics
Responsible party
Sponsor
First posted
Aug 7, 2009
Start date
Dec 2009
Primary completion
Jul 2010
Completion
Jul 2010
Results posted
Apr 19, 2012
Last update
Feb 10, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teplizumab

Start the discussion